Your browser is no longer supported. Please, upgrade your browser.
Settings
CTLT Catalent, Inc. daily Stock Chart
CTLT [NYSE]
Catalent, Inc.
Index- P/E62.04 EPS (ttm)0.88 Insider Own0.50% Shs Outstand154.39M Perf Week-7.72%
Market Cap8.45B Forward P/E24.49 EPS next Y2.23 Insider Trans-16.14% Shs Float153.83M Perf Month-11.14%
Income129.70M PEG7.39 EPS next Q0.52 Inst Own98.00% Short Float3.31% Perf Quarter6.15%
Sales2.73B P/S3.10 EPS this Y-0.60% Inst Trans0.71% Short Ratio5.58 Perf Half Y2.95%
Book/sh11.75 P/B4.66 EPS next Y14.10% ROA2.30% Target Price70.29 Perf Year26.02%
Cash/sh- P/C- EPS next 5Y8.40% ROE7.80% 52W Range39.09 - 68.78 Perf YTD-2.81%
Dividend- P/FCF84482.21 EPS past 5Y30.50% ROI5.10% 52W High-19.80% Beta1.69
Dividend %- Quick Ratio1.60 Sales past 5Y6.60% Gross Margin31.70% 52W Low41.11% ATR1.68
Employees12300 Current Ratio2.00 Sales Q/Q15.80% Oper. Margin10.50% RSI (14)34.99 Volatility3.30% 2.87%
OptionableYes Debt/Eq1.69 EPS Q/Q-30.50% Profit Margin4.80% Rel Volume0.94 Prev Close54.72
ShortableYes LT Debt/Eq1.65 EarningsFeb 03 BMO Payout0.00% Avg Volume911.95K Price55.16
Recom1.60 SMA20-7.50% SMA50-5.29% SMA2004.22% Volume809,447 Change0.80%
Oct-17-19Resumed Stephens Overweight $56
Aug-28-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jun-21-19Upgrade Jefferies Hold → Buy $50 → $62
Apr-16-19Upgrade UBS Neutral → Buy $43 → $54
Nov-07-18Upgrade First Analysis Sec Neutral → Outperform $47 → $43
Oct-09-18Initiated UBS Neutral
Mar-28-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Mar-21-18Upgrade Raymond James Mkt Perform → Outperform
Feb-06-18Downgrade Stephens Overweight → Equal-Weight
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-17Initiated Needham Hold
Sep-08-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Dec-01-16Initiated Goldman Neutral
Oct-20-16Initiated KeyBanc Capital Mkts Overweight $29
Jun-21-16Upgrade Wells Fargo Market Perform → Outperform
Jun-20-16Upgrade BofA/Merrill Neutral → Buy
May-05-16Downgrade BofA/Merrill Buy → Neutral
Apr-21-16Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-16Reiterated Deutsche Bank Hold $31 → $24
Dec-22-15Downgrade Wells Fargo Outperform → Market Perform
Feb-20-20 01:04PM  Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2028 Business Wire
Feb-19-20 04:16PM  Catalent Pharma Solutions, Inc. -- Moody's assigns B3 rating to Catalent's notes offering Moody's
07:21AM  The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga
02:55AM  Catalent Announces Launch of Private Offering of 450 Million of Senior Unsecured Notes Due 2028 Business Wire
Feb-18-20 04:05PM  Catalent, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-16-20 04:07PM  Top Insider Buys Highlight for the Week of Feb. 14 GuruFocus.com
Feb-11-20 05:43AM  Edited Transcript of CTLT earnings conference call or presentation 3-Feb-20 1:15pm GMT Thomson Reuters StreetEvents
Feb-10-20 04:15PM  Catalent Completes Acquisition of MaSTherCell Business Wire
Feb-05-20 05:54AM  US$70.88 - That's What Analysts Think Catalent, Inc. Is Worth After These Results Simply Wall St.
Feb-04-20 07:51AM  The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares Benzinga
Feb-03-20 06:48PM  Catalent, Inc. Announces Pricing of Public Offering of Common Stock Business Wire
04:12PM  Catalent, Inc. Announces Public Offering of Common Stock Business Wire
10:32AM  Catalent To Buy Cell Therapy CDMO MasTherCell For $315M Benzinga
08:55AM  Catalent (CTLT) Matches Q2 Earnings Estimates Zacks
07:30AM  Catalent, Inc. Reports Second Quarter Fiscal 2020 Results Business Wire
07:29AM  Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform Business Wire
Jan-27-20 12:30PM  Catalent (CTLT) Reports Next Week: What You Should Expect Zacks
07:16AM  Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT) Simply Wall St.
Jan-16-20 04:15PM  Catalent Further Strengthens Biologics Business with Key Senior Appointments Business Wire
Jan-15-20 04:15PM  Catalent, Inc. Announces Second Quarter Fiscal Year 2020 Earnings Conference Webcast Business Wire
Jan-13-20 01:02PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Jan-09-20 08:37AM  2019 Review: Top Hedge Fund Stocks vs. Catalent Inc (CTLT) Insider Monkey
Jan-07-20 04:15PM  Catalent, Inc. to Present at the 38th Annual J.P. Morgan Health Care Conference Business Wire
Dec-31-19 09:04AM  How Many Catalent, Inc. (NYSE:CTLT) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Dec-06-19 12:39PM  Hedge Funds Piled Into Catalent Inc (CTLT) Just In Time Insider Monkey
Dec-03-19 07:10AM  With EPS Growth And More, Catalent (NYSE:CTLT) Is Interesting Simply Wall St.
Nov-21-19 02:40AM  Edited Transcript of CTLT earnings conference call or presentation 5-Nov-19 1:15pm GMT Thomson Reuters StreetEvents
Nov-10-19 05:54AM  3 Monster Growth Stocks That Are Still Undervalued TipRanks
Nov-05-19 08:55AM  Catalent (CTLT) Surpasses Q1 Earnings and Revenue Estimates Zacks
07:30AM  Catalent, Inc. Reports First Quarter Fiscal 2020 Results Business Wire
Nov-04-19 11:23AM  Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More Zacks
Oct-31-19 03:00AM  Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases Using Zydis ODT Technology Business Wire
Oct-30-19 12:57PM  Ken Fisher's Top 5 Buys for the 3rd Quarter GuruFocus.com
07:28AM  The Catalent (NYSE:CTLT) Share Price Has Gained 125%, So Why Not Pay It Some Attention? Simply Wall St.
Oct-29-19 10:33AM  Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline Zacks
Oct-28-19 09:30AM  CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Oct-17-19 02:49PM  Paragon growing quickly toward 1,000 employees after Catalent acquisition American City Business Journals
10:11AM  Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2% Zacks
Oct-14-19 08:10PM  Is Catalent Inc (CTLT) A Good Stock To Buy? Insider Monkey
Oct-10-19 09:30AM  CTLT or NBIX: Which Is the Better Value Stock Right Now? Zacks
Oct-09-19 04:15PM  Catalent, Inc. Announces First Quarter Fiscal Year 2020 Earnings Conference Webcast Business Wire
Oct-07-19 10:03AM  Is Catalent, Inc.'s (NYSE:CTLT) High P/E Ratio A Problem For Investors? Simply Wall St.
Sep-13-19 08:34AM  Does Catalent (NYSE:CTLT) Have A Healthy Balance Sheet? Simply Wall St.
Sep-06-19 09:40AM  JAZZ vs. CTLT: Which Stock Is the Better Value Option? Zacks
Sep-04-19 09:15AM  Lannett (LCI) Hits 52-Week High, Can the Run Continue? Zacks
Sep-02-19 09:00AM  Catalent (CTLT) Upgraded to Buy: Here's Why Zacks
04:39AM  Edited Transcript of CTLT earnings conference call or presentation 27-Aug-19 12:15pm GMT Thomson Reuters StreetEvents
Aug-28-19 02:42PM  Catalent Analyst Cites Valuation Concerns In Downgrade Benzinga
Aug-27-19 04:20PM  This Surging Medical Stock Beats Views, But Shares Take A Breather Investor's Business Daily
12:23PM  Catalent Inc (CTLT) Q4 2019 Earnings Call Transcript Motley Fool
08:55AM  Catalent (CTLT) Surpasses Q4 Earnings and Revenue Estimates Zacks
07:48AM  Catalent Reports Q4 Earnings Beat Benzinga
07:30AM  Catalent, Inc. Reports Fourth Quarter Fiscal 2019 Results Business Wire
Aug-26-19 02:35PM  Catalent's Q4 Earnings Outlook Benzinga
01:13PM  What Are Analysts Saying About Catalent, Inc.'s (NYSE:CTLT) Growth? Simply Wall St.
Aug-21-19 12:55PM  10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar InvestorPlace
06:11AM  Read This Before Judging Catalent, Inc.'s (NYSE:CTLT) ROE Simply Wall St.
Aug-20-19 10:30AM  Earnings Preview: Catalent (CTLT) Q4 Earnings Expected to Decline Zacks
Aug-19-19 10:10AM  Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock? Zacks
Aug-16-19 10:49AM  Medtronic (MDT) to Report Q1 Earnings: What's in Store? Zacks
Aug-09-19 10:42AM  Tilray (TLRY) to Report Q2 Earnings: What's in the Cards? Zacks
Aug-07-19 06:32PM  Novavax looks to next flu vaccine trial following sale of manufacturing business American City Business Journals
Jul-31-19 10:10AM  Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again Zacks
Jul-17-19 04:15PM  Catalent, Inc. Announces Fourth Quarter Fiscal Year 2019 Earnings Conference Webcast Business Wire
Jul-15-19 09:30AM  CTLT vs. ZTS: Which Stock Is the Better Value Option? Zacks
Jul-12-19 01:42PM  Here's Why Catalent Stock Soared 73.9% in the First Half of 2019 Motley Fool
Jul-09-19 07:00AM  Catalent Extends Global Commercial Spray Drying Capabilities in Europe Business Wire
Jun-27-19 07:00AM  Novavax selling manufacturing business amid good news for flu vaccine American City Business Journals
Jun-24-19 02:56PM  Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027 Business Wire
02:03PM  Catalent Pharma Solutions, Inc. -- Moody's assigns B3 rating to Catalent's notes offering Moody's
07:24AM  Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027 Business Wire
Jun-23-19 04:10PM  Did Hedge Funds Drop The Ball On Catalent Inc (CTLT) ? Insider Monkey
Jun-19-19 09:00AM  Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock? Zacks
06:59AM  Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy Business Wire
May-30-19 04:15PM  Catalent, Inc. to Present at the Jefferies Healthcare Conference Business Wire
May-21-19 08:52AM  Catalent Acquires Gene Therapy Leader Paragon Bioservices Zacks
May-20-19 08:30AM  Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion Business Wire
May-13-19 02:35AM  Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT Thomson Reuters StreetEvents
May-09-19 02:20PM  Catalent Pharma Solutions, Inc. -- Moody's downgrades Catalent's senior secured rating to Ba3, affirms B1 CFR rating; the outlook remains stable Moody's
May-07-19 02:23PM  Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript Motley Fool
08:55AM  Catalent (CTLT) Surpasses Q3 Earnings Estimates Zacks
07:45AM  Catalent: Fiscal 3Q Earnings Snapshot Associated Press
07:30AM  Catalent, Inc. Reports Third Quarter Fiscal 2019 Results Business Wire
Apr-30-19 10:32AM  Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-24-19 10:52AM  Did Hedge Funds Drop The Ball On Catalent Inc (CTLT) ? Insider Monkey
Apr-17-19 04:05PM  Catalent Pharma Solutions, Inc. -- Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc. Moody's
11:37AM  Catalent Pharma Solutions, Inc. -- Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative Moody's
Apr-15-19 03:33PM  Catalent seeks slice of gene therapy market with Paragon buy Reuters +13.12%
09:53AM  Catalent to Buy Paragon Bioservices for $1.2 Billion TheStreet.com
09:27AM  Catalent Agrees To Buy Gene Therapy-Focused CDMO Paragon Services For $1.2B Benzinga
08:12AM  Stocks making the biggest moves premarket: Goldman Sachs, CVS, Best Buy, Facebook & more CNBC
07:38AM  Catalent pushes into gene therapy with $1.2 bln buyout of Paragon Bioservices Reuters
07:15AM  Catalent to acquire Paragon Bioservices for $1.2 billion in cash MarketWatch
07:13AM  Catalent to buy Paragon Bioservices for $1.2 bln Reuters
07:02AM  Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion PR Newswire
07:00AM  Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion Business Wire
Apr-14-19 11:17PM  Catalent to buy Paragon Bioservices for $1.2 billion - WSJ Reuters
07:42PM  Catalent to buy Paragon Bioservices for $1.2 bln - WSJ Reuters
07:39PM  Catalent to buy Paragon Bioservices for $1.2 bln -WSJ Reuters
06:08PM  Catalent to buy Paragon Bioservices for $1.2 bln -WSJ Reuters
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LUCIER GREGORY TDirectorFeb 13Buy59.712,000119,42040,921Feb 14 02:43 PM
Maselli AlessandroPresident & COODec 16Sale53.187,268386,51212,802Dec 18 08:51 AM
Pravda RicardoSVP & Chief HR OfficerNov 26Sale52.732,612137,71810,846Nov 27 11:36 AM
Gennadios AristipposPresident Softgel & Oral TechNov 25Option Exercise18.35123,8802,272,760141,122Nov 27 11:36 AM
Gennadios AristipposPresident Softgel & Oral TechNov 25Sale52.5545,2562,378,20344,241Nov 27 11:36 AM
Grippo Michael JSVP, Strategy & Corp. Dev.Nov 22Sale52.0037619,55210,702Nov 26 05:07 PM
Chiminski John RChair & CEOOct 07Option Exercise24.4047,5521,160,409348,387Oct 09 01:13 PM
Chiminski John RChair & CEOOct 07Sale48.8497,0434,739,580224,257Oct 09 01:13 PM
LUCIER GREGORY TDirectorSep 09Buy51.642,000103,28038,921Sep 11 08:30 AM
Littlejohns BarryPresident, Biologics & SDDJul 12Option Exercise19.3649,212952,93867,562Jul 16 07:21 PM
Littlejohns BarryPresident, Biologics & SDDJul 12Sale53.5315,940853,34437,718Jul 16 07:21 PM
Fasman Steven LSVP & General CounselJul 11Option Exercise27.3027,146741,14260,705Jul 15 06:03 PM
Fasman Steven LSVP & General CounselJul 11Sale54.044,053219,02448,528Jul 15 06:03 PM
BUZY PETER LPresident, Gene TherapyMay 29Buy45.1344,5002,008,28544,500May 30 07:36 PM
Joseph WettenySVP & Chief Financial OfficerMay 28Option Exercise10.719,453101,24242,060May 30 06:54 PM
MOREL DONALD E JRDirectorMay 15Buy44.4410,000444,40046,958May 16 07:51 PM
LUCIER GREGORY TDirectorMay 09Buy45.082,00090,16038,822May 13 01:39 PM
Gennadios AristipposPresident, Softgel Tech.Mar 21Option Exercise10.7113,528144,88544,862Mar 25 05:50 PM
Gennadios AristipposPresident, Softgel Tech.Mar 21Sale42.183,392143,08934,726Mar 25 05:50 PM
Miyamoto LanceSVP, Human ResourcesMar 07Option Exercise15.34123,6101,896,337130,793Mar 11 07:31 PM
Miyamoto LanceSVP, Human ResourcesMar 07Sale42.4943,6191,853,37846,799Mar 11 07:31 PM